Saturday, May 27, 2017
Tailwinds Take: a well written article by David Templeton of the Pittsburgh Post-Gazette that discusses the work of Dr. Sabine Mai in conjunction with Dr. Hans Knecht on the use of telomeres in cancer diagnostics. Discovery, the goal of science,...
3D Signatures is using telomeres to help diagnose many forms of cancer, including prostate. Hear what they're doing in prostate as well as catalysts for the rest of the year, in this video with CEO Jason Flowerday.
As CEO of 3D Signatures (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) since last September, Jason Flowerday is putting the diagnostic company on people’s radar. Unlike most diagnostic companies, 3DS’ proprietary imaging software, known as TeloView, goes beyond identifying whether a patient suffers...
Tailwinds' Take: This is a major milestone for 3DS as PRECISE is the first ever large-scale multi-center study focused on men with a clinical suspicion of prostate cancer. It serves to validate their diagnostic technology among potential prostate cancer patients, a huge...
At Tailwinds, we are focused on finding future leaders. Companies that fit our model bring new technologies to growing markets. The combination of disruptive technologies with expanding end markets gives our portfolio companies the opportunity to grow at multiples...
WINNIPEG, Manitoba, April 18, 2017 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), is pleased to announce that the Company will relocate its corporate offices to the MaRS Discovery District (“MaRS”) in Toronto this...
In this short video, understand how 3DS' groundbreaking 3D Telomere Technology uses chromosomal alignments to diagnose multiple diseases.
WINNIPEG, Manitoba, April 11, 2017 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), is pleased to announce the appointment of Dr. Kevin Little, subject to approval of the TSX Venture Exchange, a leading biomedical...
We are adding shares of 3D Signatures (DXD.V) to the Tailwinds Select Portfolio as of the end of March, 2017 at a share price of $.70 CDN. 3D Signatures is a personalized medicine company with a proprietary software platform based...
Tailwinds' Take: while not a huge milestone, this is another step forward towards full FDA product approval. 3DS is proving, with every positive result, that they are developing the most effective diagnostic tools in the industry. WINNIPEG, Manitoba, March 29,...
Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address